HealthVerity taXonomy webinar recap: Claim better outcomes
As the industry develops increasingly complex treatments to address unmet clinical needs, it is...
7 minute read
The biomarker advantage
HealthVerity COO Andrew Goldberg recently sat down with Quest Diagnostics’ Director, Health...
5 minute read
Open claims vs. closed payer claims: What’s the difference?
Open claims and closed payer claims data are essential for understanding the status and activities...
4 minute read
Manageable medical device monitoring with real-world data
The FDA often requires some sort of post-market surveillance for medical devices to determine the...
2 minute read
Mastering precision, not indecision in real-world data
Real-world data (RWD) offers a multitude of use cases that can benefit pharmaceutical companies...
6 minute read
Enhancing go-to-market strategies with real-world data
Our series exploring the value of real-world data (RWD) throughout the pharmaceutical product life...
4 minute read
Extending value long after the clinical trial with real-world data
In our ongoing series, we have been discussing the value of real-world data (RWD) throughout the...
2 minute read
Honoring MOM: How far we've come
Two years ago, HealthVerity launched the Maternal Outcomes Masterset (MOM) to address the...
2 minute read
Diversity on demand: How to meet new FDA guidance for clinical trials
The FDA recently released draft guidance that provides details on creating Diversity Action Plans (DAPs) for clinical trials. This is part of a continuing effort to address ongoing challenges in broadening diversity and ensuring that clinical trials ...
- Solutions & Best Practices
- Industry Updates by:HealthVerity on: July 24, 2024